Skip to main content
Premium Trial:

Request an Annual Quote

Serenex Broadens Proteomic Profiling Services for GSK

NEW YORK, Jan. 11 (GenomeWeb News) - Serenex has broadened its deal with GlaxoSmithKline, providing the drug maker with compound-profiling services using its purine proteomics technology, the Durham, NC-based company said today.


GSK scientists at any location can now submit compounds to Serenex, which will profile them against specific tissues and cell lines using its Proteome Mining Technology. The technology allows scientists to study the specificity of compounds for purine-binding proteins.


Serenex signed its first deal with GSK in 2003. The new agreement "will enable Serenex to more fully apply its technology to a larger number of GSK programs," said Serenex CEO Richard Kent in a statement.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.